Astellas Pharma Inc. (Tokyo Stock Exchange: 4503.T) – Market Snapshot and Recent Corporate Developments
Market Performance (24 h ending 09:37 PM Central Europe, Wednesday 21 Oct 2026)
- Price change: Up 0.39 %
- Current price: ¥2,490.5 per share (traded on major exchanges)
- Shares outstanding: 1.8 bn
- Market capitalization: ¥4.4 trillion
- Volume: ¥11.7 bn worth of shares exchanged
- Monthly performance: Up 2.14 % since the previous month‑end
- Technical indicators:
- 200‑day simple moving average: ¥2,312.58
- 52‑week high: ¥2,717 (08 Apr 2026)
- 52‑week low: ¥1,557.5 (30 Oct 2025)
Corporate Announcement – IDWeek 2026 Presentations
Basel‑based Astellas Pharma Inc. has confirmed that its anti‑infective pipeline will be highlighted during the IDWeek conference in Washington, D.C. (21‑24 Oct 2026). The schedule includes:
| Program | Focus | Details |
|---|---|---|
| Phase‑3 antifungal | Fosmanogepix | Data presentation |
| Established antifungal | Cresemba | Updated efficacy and safety |
| Antibacterial | Zevtera | Real‑world safety observations |
| Pediatric studies | Activity against resistant fungal isolates | |
| Collaborations | Joint studies with independent researchers |
The company emphasized that the presentations aim to reinforce scientific evidence for its products and address unmet needs in severe bacterial and fungal infections.
Related Japanese Shares – 24‑Hour Performance
| Ticker | Price Change | Current Price (JPY) | Market Capitalisation | P/E Ratio | Notes |
|---|---|---|---|---|---|
| 3382.T (Seven & I) | +2.06 % | 2,094 | 4.8 trillion | 16.7 | |
| 6971.T (Kyocera) | –3.86 % | 3,552 | 4.5 trillion | 28.74 | Shares fell as Nikkei 225 slid below 64,150; broader market weakness. |
| 2802.T (Ajinomoto) | –0.63 % | 5,278 | 5 trillion | 36.16 | Joint development with bitBiome, Inc. achieved milestones; success fee received. |
| 4062.T (Ibiden) | –3.57 % | 9,500 | 5.2 trillion | 77.81 | |
| 4568.T (Daiichi Sankyo) | +2.19 % | 2,841 | 5.2 trillion | 21.21 | Positioned in expanding lipid‑lowering sector; focus on triglyceride metabolism. |
Company Overview
Astellas Pharma Inc. is a global pharmaceutical company headquartered in Basel, Switzerland, with operations in the United States, Europe, and Asia. The company’s therapeutic focus areas include:
- Urology
- Immunology (including transplantation)
- Infectious diseases
- Oncology
- Metabolic disorders (e.g., diabetes mellitus complications)
- Other specialty areas
Astellas develops, manufactures, and markets prescription drugs through subsidiaries and partners worldwide. The company’s initial public offering occurred on 1 May 1949, and it is listed on the Tokyo Stock Exchange (ticker 4503.T). For further details, visit the corporate website at www.astellas.com .
